Search

Displaying results 4441 - 4450 of 10000 in total
  1. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).

  2. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol. … ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes.

  3. Drug

    Interferon Gamma

    go.drugbank.com/drugs/DB15753
    Investigational

    Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. … The interferon is primarily produced by activated T lymphocytes and natural killer cells.

    Synonyms: IFN-G, IFN-γ
  4. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro. … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  5. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]

  6. Drug

    Stamulumab

    go.drugbank.com/drugs/DB05915
    Investigational

    MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.

  7. Drug

    Contusugene ladenovec

    go.drugbank.com/drugs/DB05322
    Investigational

    INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. … Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.

  8. Drug

    Mitonafide

    go.drugbank.com/drugs/DB19492
    Experimental

    Mitonafide is a small molecule drug. Mitonafide has a monoisotopic molecular weight of 313.11 Da.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Oxidronic acid

    go.drugbank.com/drugs/DB14159
    Approved

  10. Drug

    Romlusevimab

    go.drugbank.com/drugs/DB16494
    Investigational

    Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.